Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
TGen and Baylor partnership set to increase treatment options for cancer patients

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers. [More]
BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform. [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
Researchers discover how and where chromosome fragile sites occur in human DNA

Researchers discover how and where chromosome fragile sites occur in human DNA

Using a novel method they developed to map chromosome breaks in a model organism, the budding yeast, Wenyi Feng, Ph.D., of Upstate Medical University and her colleagues have discovered new information as to how and where chromosome fragile sites can occur in human DNA. These sites are frequently observed in cancer cells and are responsible for causing genomic rearrangements. [More]
Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and Texas Children's Hospital have found that a single dose of an otherwise harmless drug can safely control the severe and often lethal side effects associated with haploidentical stem cell transplantation. [More]
Researchers explore how low-level electrical stimulation reduces inflammation

Researchers explore how low-level electrical stimulation reduces inflammation

The Feinstein Institute for Medical Research, the research arm of the North Shore-LIJ Health System, and SetPoint Medical Inc., a biomedical technology company, today released the results of research on the therapeutic potential of vagus nerve stimulation. In a paper published by Bioelectronic Medicine, Kevin J. Tracey, MD, and his colleagues at the Feinstein Institute, explore how low-level electrical stimulation interacts with the body's nerves to reduce inflammation, a fundamental goal of bioelectronic medicine. [More]
Researchers submit patent application for drug that could destroy acute lymphoblastic leukemia

Researchers submit patent application for drug that could destroy acute lymphoblastic leukemia

A patent application for a drug that could destroy the deadly childhood disease known as acute lymphoblastic leukemia — and potentially other cancers as well — has been submitted by researchers at Sandia National Laboratories, the University of Maryland and the MD Anderson Cancer Center in Houston. [More]
Childhood cancer survivors more likely to be obese than healthy peers

Childhood cancer survivors more likely to be obese than healthy peers

Childhood cancer survivors - especially those whose treatment included brain irradiation or chemotherapy with glucocorticoids - are 14 percent more likely to be obese than their healthy peers. [More]
MD Anderson researchers discover link between telomere degeneration and MDS

MD Anderson researchers discover link between telomere degeneration and MDS

A study revealing fresh insight about chromosome "tails" called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes (MDS). [More]
New study finds link between father's age at birth and child's risk of blood cancer as an adult

New study finds link between father's age at birth and child's risk of blood cancer as an adult

A new study links a father's age at birth to the risk that his child will develop blood and immune system cancers as an adult, particularly for only children. The study, which appears in the American Journal of Epidemiology, found no association between having an older mother and these cancers. [More]
Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells. [More]
Researchers identify promising combination strategy for treating glioblastomas

Researchers identify promising combination strategy for treating glioblastomas

Therapies that specifically target mutations in a person's cancer have been much-heralded in recent years, yet cancer cells often find a way around them. To address this, researchers at University of California, San Diego School of Medicine and Moores Cancer Center identified a promising combinatorial approach to treating glioblastomas, the most common form of primary brain cancer. [More]
New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally. [More]
Overexpression of cyclin E protein could lead to breast cancer, leukemia

Overexpression of cyclin E protein could lead to breast cancer, leukemia

A new study led by scientists at The Scripps Research Institute sheds light on the cause of some cancers, including breast cancer and leukemia. [More]
Quest Diagnostics launches genomic test service that aids in diagnosis for myeloid neoplasms

Quest Diagnostics launches genomic test service that aids in diagnosis for myeloid neoplasms

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that includes acute myeloid leukemia (AML), the most common form of adult acute leukemia, as well as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs). [More]
AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

AbbVie's venetoclax granted FDA Breakthrough Therapy Designation for CLL patients with 17p deletion

AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation. [More]
St. Jude scientists develop new computer tool to find DNA duplications and deletions in tumors

St. Jude scientists develop new computer tool to find DNA duplications and deletions in tumors

St. Jude Children's Research Hospital scientists have developed a significantly better computer tool for finding genetic alterations that play an important role in many cancers but were difficult to identify with whole-genome sequencing. [More]
Researchers identify mechanism responsible for steroid resistance in leukemia patients

Researchers identify mechanism responsible for steroid resistance in leukemia patients

Researchers led by St. Jude Children's Research Hospital scientists have identified a mechanism that helps leukemia cells resist glucocorticoids, a finding that lays the foundation for more effective treatment of cancer and possibly a host of autoimmune diseases. [More]
DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar Pharmaceuticals, Inc., today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois. [More]
ITIM-containing receptor crucial for development of acute myeloid leukemia

ITIM-containing receptor crucial for development of acute myeloid leukemia

UT Southwestern Medical Center scientists have discovered that a certain class of receptors that inhibit immune response are crucial for the development of acute myeloid leukemia (AML), the most common acute leukemia affecting adults. [More]
Advertisement